Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early treatment intensification in FDG-PET positive high-risk Hodgkin lymphoma after two ABVD cycles
2007-007168-94Phase 2Active
- Sponsor
- Ospedale Santa Croce e Carle
- Start
- Jun 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, bleomycin, vinblastine and dacarbazine in Hodgkin lymphoma (HL), sponsored by Ospedale Santa Croce e Carle. Primary endpoints: 3-year progression-free survival and 3-year event-free survival. Started Jun 2008; status: active.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2007-007168-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007168-94.